The combination of Bosutinib with the PI3Kα inhibitor Alpelisib, which has shown good efficacy and tolerability in several cancers, including HNSCC [17,18,19], efficiently inhibited both EGFR/ERK and PI3K pathways in HNSCC cell lines. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.